Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04 2024 - 4:10PM
PARIS, France, June 4, 2024 –
Abivax SA (Euronext Paris & Nasdaq: ABVX)
(“Abivax” or the “Company”), a
clinical-stage biotechnology company focused on developing
therapeutics that harness the body’s natural regulatory mechanisms
to stabilize the immune response in patients with chronic
inflammatory diseases, held its ordinary and extraordinary general
meeting of shareholders on May 30, 2024 (the “General
Meeting”), which was chaired by Mr. Marc de Garidel, CEO
and Chairman of the Board of Directors of Abivax
(“Board”).
The shareholders have adopted all the
resolutions proposed by the Board and, in particular, the financial
statements for the 2023 financial year, the compensation policy
applicable to the Chairman, the Chief Executive Officer and the
directors, as well as delegations granted to the Board related to
financial transactions.
The shareholders have also ratified the
appointment of Mr. Troy Ignelzi, Dr. June Lee and Ms. Camilla
Soenderby as Board members.
Details on the vote results will be available on
the Company’s website (www.abivax.com).
About Obefazimod
Obefazimod, Abivax’s lead investigational drug
candidate, is an orally administered small molecule that was
demonstrated to potentially enhance the expression of a single
microRNA, miR-124. Phase 2 clinical trials in patients with UC have
generated positive data, resulting in the initiation of a pivotal
global Phase 3 clinical trial program (ABTECT Program), with first
patients enrolled in the United States in October 2022. Initiation
of a Phase 2b clinical trial in Crohn’s disease is expected in
Q3 2024, and exploration of potential combination therapy
opportunities in UC is ongoing.
About Abivax
Abivax is a clinical-stage biotechnology company
focused on developing therapeutics that harness the body’s natural
regulatory mechanisms to stabilize the immune response in patients
with chronic inflammatory diseases. Based in France and the United
States, Abivax’s lead drug candidate, obefazimod (ABX464), is in
Phase 3 clinical trials for the treatment of moderately to severely
active ulcerative colitis. More information on the Company is
available at www.abivax.com. Follow us on LinkedIn and on X,
formerly Twitter, @Abivax.
Contact
Abivax Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878
Abivax Communications
communications@abivax.com
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, forecasts and estimates, including those relating to
the Company’s business and financial objectives. Words such as
“expect,” “potential,” “will” and variations of such words and
similar expressions are intended to identify forward-looking
statements. Although Abivax’s management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks,
contingencies and uncertainties, many of which are difficult to
predict and generally beyond the control of Abivax, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. A description of these risks,
contingencies and uncertainties can be found in the documents filed
by the Company with the French Autorité des Marchés Financiers
pursuant to its legal obligations including its universal
registration document (Document d’Enregistrement Universel) and in
the Company’s Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission on April 5, 2024 under the
caption “Risk Factors.” These risks, contingencies and
uncertainties include, among other things, the uncertainties
inherent in research and development, future clinical data and
analysis, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug candidate,
as well as their decisions regarding labelling and other matters
that could affect the availability or commercial potential of such
product candidates. Special consideration should be given to the
potential hurdles of clinical and pharmaceutical development
including further assessment by the company and regulatory agencies
and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data.
Furthermore, these forward-looking statements, forecasts and
estimates are only as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Abivax disclaims any obligation to update these
forward-looking statements, forecasts or estimates to reflect any
subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products
(including products currently in development) that is included in
this press release is not intended to constitute an
advertisement. This press release is for information purposes
only, and the information contained herein does not constitute
either an offer to sell, or the solicitation of an offer to
purchase or subscribe securities of the Company in any
jurisdiction. Similarly, it does not give and should not be treated
as giving investment advice. It has no connection with the
investment objectives, financial situation or specific needs of any
recipient. It should not be regarded by recipients as a substitute
for exercise of their own judgment. All opinions expressed herein
are subject to change without notice. The distribution of this
document may be restricted by law in certain jurisdictions. Persons
into whose possession this document comes are required to inform
themselves about and to observe any such restrictions.
Abivax (NASDAQ:ABVX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Abivax (NASDAQ:ABVX)
Historical Stock Chart
From Aug 2023 to Aug 2024